Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Togo to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). As the population continues to grow, the demand for these drugs is also increasing.
Customer preferences: Customers in Togo prefer bronchodilator drugs that are affordable and effective. Due to the low per capita income in the country, many people cannot afford expensive medications. Therefore, customers tend to purchase generic versions of bronchodilator drugs that are more affordable.
Trends in the market: The bronchodilator drugs market in Togo is experiencing a steady growth due to the increasing prevalence of respiratory diseases. The market is expected to continue growing in the coming years as the population continues to grow. The demand for bronchodilator drugs is also expected to increase due to the high levels of air pollution in some parts of the country.
Local special circumstances: Togo is a small West African country with a population of over 8 million people. The country has a relatively low per capita income, which means that many people cannot afford expensive medications. The healthcare system in Togo is also underdeveloped, which means that many people do not have access to proper healthcare facilities. This has led to a high prevalence of respiratory diseases in the country.
Underlying macroeconomic factors: The economy of Togo is heavily dependent on agriculture, which accounts for over 40% of the country's GDP. The country also has a small industrial sector, which is mainly focused on processing agricultural products. The low per capita income in the country means that many people cannot afford expensive medications, which has led to a high demand for generic drugs. The government of Togo has implemented policies to improve access to healthcare, which is expected to increase the demand for bronchodilator drugs in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
